Applied Genetic Technologies (AGTC) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
AGTC Announces Financial Results for the Second Quarter Ended December 31, 2014
February 11, 2015 8:00 AM ESTGAINESVILLE, Fla., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the second quarter ended December 31, 2014.
"We are rapidly advancing our lead programs X-linked retinoschisis (XLRS) and achromatopsia (ACHM) toward Phase I/II clinical trials and expect to see initial clinical results for both programs during the second half of 2015," said Sue Washer, President and CEO. "We are also advancing preclinical studies for our product candidate addressing X-linked retinitis... More
